Company record · updated August 5, 2026
Recursion Pharmaceuticals, Inc.: 6 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs March 22, 2021 to April 12, 2021.
6observations
2source filings
6verified rows
2021-04-12most recent as-of date
Source rails for this company: S-1 charter round (6).
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2021-04-12 | Series D price per share | 6.7079 USD | — | VERIFIED | "Original Issue Price" defined for Series D | 000119312521112364 |
| 2021-04-12 | Series C price per share | 6.5006 USD | — | VERIFIED | "Original Issue Price" defined for Series C | 000119312521112364 |
| 2021-04-12 | Series B price per share | 2.7944 USD | — | VERIFIED | "Original Issue Price" defined for Series B | 000119312521112364 |
| 2021-03-22 | Series D price per share | 10.0618 USD | — | VERIFIED | "Original Issue Price" defined for Series D | 000119312521089610 |
| 2021-03-22 | Series C price per share | 9.7509 USD | — | VERIFIED | "Original Issue Price" defined for Series C | 000119312521089610 |
| 2021-03-22 | Series B price per share | 4.1915 USD | — | VERIFIED | "Original Issue Price" defined for Series B | 000119312521089610 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.